| pubmed-article:12928113 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12928113 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:12928113 | lifeskim:mentions | umls-concept:C1512505 | lld:lifeskim |
| pubmed-article:12928113 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:12928113 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:12928113 | lifeskim:mentions | umls-concept:C0679083 | lld:lifeskim |
| pubmed-article:12928113 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12928113 | pubmed:dateCreated | 2003-8-20 | lld:pubmed |
| pubmed-article:12928113 | pubmed:abstractText | During cytotoxic chemotherapy, cancer cells are exposed to a dynamic concentration-versus-time curve. Besides the area under this curve, the shape of this curve may determine the cytotoxic effect. This report describes the concept that cell damage is determined by the molar drug accumulation history inside the tumor cells. Cell numbers of large populations of human MCF-7 cells exposed to three different doxorubicin concentration-versus-time profiles were recorded for 31 days. The drug accumulation history in the cells was calculated using cellular drug transport parameters derived from doxorubicin uptake and efflux measurements on MCF-7 cells attached to culture dishes. Recovery of the proliferation rate of a cell population after drug exposure was described using a mathematical model of cell damage. The model fitted well to the proliferation assays. It allowed for comparison of the effects of changes in doxorubicin concentration-versus-time profiles in vitro. The model was then used to predict the effect of the changes in the doxorubicin concentration profile in vivo, in tumor islets, after a bolus injection of doxorubicin. In the model doxorubicin exposure resulted in less cell damage inside the tumor islets than at the rim. | lld:pubmed |
| pubmed-article:12928113 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12928113 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12928113 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12928113 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12928113 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12928113 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12928113 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:12928113 | pubmed:issn | 0006-3002 | lld:pubmed |
| pubmed-article:12928113 | pubmed:author | pubmed-author:PinedoHerbert... | lld:pubmed |
| pubmed-article:12928113 | pubmed:author | pubmed-author:LankelmaJanJ | lld:pubmed |
| pubmed-article:12928113 | pubmed:author | pubmed-author:DekkerHenkH | lld:pubmed |
| pubmed-article:12928113 | pubmed:author | pubmed-author:Fernández... | lld:pubmed |
| pubmed-article:12928113 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12928113 | pubmed:day | 22 | lld:pubmed |
| pubmed-article:12928113 | pubmed:volume | 1622 | lld:pubmed |
| pubmed-article:12928113 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12928113 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12928113 | pubmed:pagination | 169-78 | lld:pubmed |
| pubmed-article:12928113 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12928113 | pubmed:meshHeading | pubmed-meshheading:12928113... | lld:pubmed |
| pubmed-article:12928113 | pubmed:meshHeading | pubmed-meshheading:12928113... | lld:pubmed |
| pubmed-article:12928113 | pubmed:meshHeading | pubmed-meshheading:12928113... | lld:pubmed |
| pubmed-article:12928113 | pubmed:meshHeading | pubmed-meshheading:12928113... | lld:pubmed |
| pubmed-article:12928113 | pubmed:meshHeading | pubmed-meshheading:12928113... | lld:pubmed |
| pubmed-article:12928113 | pubmed:meshHeading | pubmed-meshheading:12928113... | lld:pubmed |
| pubmed-article:12928113 | pubmed:meshHeading | pubmed-meshheading:12928113... | lld:pubmed |
| pubmed-article:12928113 | pubmed:meshHeading | pubmed-meshheading:12928113... | lld:pubmed |
| pubmed-article:12928113 | pubmed:meshHeading | pubmed-meshheading:12928113... | lld:pubmed |
| pubmed-article:12928113 | pubmed:meshHeading | pubmed-meshheading:12928113... | lld:pubmed |
| pubmed-article:12928113 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12928113 | pubmed:articleTitle | Simulation model of doxorubicin activity in islets of human breast cancer cells. | lld:pubmed |
| pubmed-article:12928113 | pubmed:affiliation | Department of Medical Oncology, VU medical center, Room BR232, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. j.lankelma@vumc.nl | lld:pubmed |
| pubmed-article:12928113 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12928113 | lld:pubmed |
